• MANORMA Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-2, Institutional Area, Greater Noida, Uttar Pradesh 201306, India
  • RUPA MAZUMDER Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-2, Institutional Area, Greater Noida, Uttar Pradesh 201306, India
  • ANJNA RANI Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-2, Institutional Area, Greater Noida, Uttar Pradesh 201306, India
  • RAJAT BUDHORI Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-2, Institutional Area, Greater Noida, Uttar Pradesh 201306, India
  • AYUSHI KAUSHIK Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-2, Institutional Area, Greater Noida, Uttar Pradesh 201306, India



Ophthalmic formulations, Diabetes mellitus, Ocular complications, Cataracts, Glaucoma, Diabetic retinopathy, Macular edema


Diabetes mellitus (DM) is a metabolic disorder, whose prevalence is predicted to rise shortly. The present review focuses on the various ocular complications associated with DM, and the various ophthalmic formulation approaches developed to treat the same. Diabetic macular edema (DME), diabetic retinopathy, cataracts, and glaucoma are some of the major vision-threatening complications linked to DM. The ocular route of drug delivery has undergone several advancements in recent decades, the introduction of various novel drug delivery systems (DDS), various modifications in the existing formulation approaches, development of custom-designed personalized medications, being some of the major developments introduced in the field of ocular drug delivery. Due to the application of state-of-the-art technologies in the field of innovations related to ocular DDS, patients have been immensely benefited by the current modes of ocular treatment imparting fewer side effects, enhanced penetration, sustained drug effect, and so on. The present review includes and emphasizes the gradual development that has occurred from the conventional ophthalmic dosage forms to the currently reported novel ocular drug delivery approaches along with the related clinical research works.


Download data is not yet available.


Kelkar A, Kelkar J, Mehta H, Amoaku W. Cataract surgery in diabetes mellitus: A systematic review. Indian J Ophthalmol. 2018 Oct;66(10):1401-10. doi: 10.4103/ijo.IJO_1158_17, PMID 30249823.

Kharroubi AT, Darwish HM. Diabetes mellitus: the epidemic of the century. World J Diabetes. 2015 Jun 25;6(6):850-67. doi: 10.4239/wjd.v6.i6.850, PMID 26131326.

Endris T, Worede A, Asmelash D. Prevalence of diabetes mellitus, prediabetes and its associated factors in Dessie Town, Northeast Ethiopia: A community-based study. Diabetes Metab Syndr Obes. 2019 Dec 31;12:2799-809. doi: 10.2147/DMSO.S225854, PMID 32021343.

Henriques J, Vaz Pereira S, Nascimento J, Rosa PC. [Diabetic eye disease]. Acta Med Port. 2015 Jan–Feb;28(1):107-13. doi: 10.20344/amp.5361, PMID 25817504.

Sayin N, Kara N, Pekel G. Ocular complications of diabetes mellitus. World J Diabetes. 2015 Feb 15;6(1):92-108. doi: 10.4239/wjd.v6.i1.92, PMID 25685281.

Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, Lim SC, Tai ES, Mitchell P. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology. 2008 Nov;115(11):1869-75. doi: 10.1016/j.ophtha.2008. 05.014, PMID 18584872.

Kaur A, Gupta V, Christopher AF, Malik MA, Bansal P. Nutraceuticals in prevention of cataract- An evidence based approach. Saudi J Ophthalmol. 2017 Jan–Mar;31(1):30-7. doi: 10.1016/j.sjopt.2016.12.001, PMID 28337060.

Peterson SR, Silva PA, Murtha TJ, Sun JK. Cataract surgery in patients with diabetes: management strategies. Semin Ophthalmol. 2018;33(1):75-82. doi: 10.1080/08820538. 2017.1353817, PMID 29144826.

Hamid S, Gul A, Hamid Q. Relationship of cytokines and AGE products in diabetic and non-diabetic patients with cataract. Int J Health Sci (Qassim). 2016 Oct;10(4):507-15. doi: 10.12816/0048891, PMID 27833515.

Gupta D, Chen PP. Glaucoma. Am Fam Physician. 2016 Apr 15;93(8):668-74. PMID 27175839.

Kiziltoprak H, Tekin K, Inanc M, Goker YS. Cataract in diabetes mellitus. World J Diabetes. 2019 Mar 15;10(3):140-53. doi: 10.4239/wjd.v10.i3.140, PMID 30891150.

Chiou SH, Chang CJ, Chou CK, Hsu WM, Liu JH, Chiang CH. Increased nitric oxide levels in aqueous humor of diabetic patients with neovascular glaucoma. Diabetes Care. 1999 May;22(5):861-2. doi: 10.2337/diacare.22.5.861a, PMID 10332703.

Zghal I, Jeddi A, Hadj Alouane WB, Malouche N, Ayed S, Gaigi S. Primary open-angle glaucoma and diabetes [Primary open-angle glaucoma and diabetes]. Tunis Med. 2000 Aug–Sep;78(8-9):518-21. PMID 11190730.

Sanders RJ, Wilson MR. Diabetes-related eye disorders. J Natl Med Assoc. 1993 Feb;85(2):104-8. PMID 8441184.

Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020 Jul 20;117(29-30):513-20. doi: 10.3238/arztebl.2020.0513, PMID 33087239.

Jung HA, Islam MD, Kwon YS, Jin SE, Son YK, Park JJ, Sohn HS, Choi JS. Extraction and identification of three major aldose reductase inhibitors from Artemisia montana. Food Chem Toxicol. 2011 Feb;49(2):376-84. doi: 10.1016/j.fct.2010.11.012, PMID 21092751.

Thiagarajan G, Venu T, Balasubramanian D. Approaches to relieve the burden of cataracts blindness through natural antioxidants: use of Ashwagandha (Withania somnifera). Curr Sci. 2003;85:1065-71.

Kinoshita JH. A thirty year journey in the polyol pathway. Exp Eye Res. 1990 Jun;50(6):567-73. doi: 10.1016/0014-4835(90)90096-d, PMID 2115448.

Grewal AS, Bhardwaj S, Pandita D, Lather V, Sekhon BS. Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases. Mini Rev Med Chem. 2016;16(2):120-62. doi: 10.2174/1389557515666150909143737, PMID 26349493.

Julius A, Hopper W. Inhibition of advanced glycation end-product formation by quercetin and catechin: an alternative therapy for treating diabetic complications. Asian J Pharm Clin Res. 2017 Nov;10(11):173-6. doi: 10.22159/ajpcr.2017.v10i11.19412.

Dixit BL, Balendiran GK, Watowich SJ, Srivastava S, Ramana KV, Petrash JM, Bhatnagar A, Srivastava SK. Kinetic and structural characterization of the glutathione-binding site of aldose reductase. J Biol Chem. 2000 Jul 14;275(28):21587-95. doi: 10.1074/jbc.M909235199, PMID 10764810.

Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos VJ. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr Med Chem. 2009;16(6):734-52. doi: 10.2174/092986709787458362, PMID 19199934.

Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res. 2003 Dec 12;93(12):1159-69. doi: 10.1161/01.RES.0000103862.26506.3D, PMID 14670831.

Srivastava S, Ramana KV, Tammali R, Srivastava SK, Bhatnagar A. Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells. Diabetes. 2006 Apr;55(4):901-10. doi: 10.2337/diabetes.55.04.06.db05-0932, PMID 16567509.

Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes. 2004 Nov;53(11):2910-20. doi: 10.2337/ diabetes.53.11.2910, PMID 15504972.

Ahmed N. Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005 Jan;67(1):3-21. doi: 10.1016/j.diabres.2004.09.004, PMID 15620429.

Stitt AW. The Maillard reaction in eye diseases. Ann N Y Acad Sci. 2005 Jun;1043:582-97. doi: 10.1196/annals.1338.066, PMID 16037281.

Ornek K, Karel F, Buyukbingol Z. May nitric oxide molecule have a role in the pathogenesis of human cataract? Exp Eye Res. 2003 Jan;76(1):23-7. doi: 10.1016/s0014-4835(02)00268-3, PMID 12589772.

Nagaraj RH, Linetsky M, Stitt AW. The pathogenic role of maillard reaction in the aging eye. Amino Acids. 2012 Apr;42(4):1205-20. doi: 10.1007/s00726-010-0778-x, PMID 20963455.

Agarwal R, Gupta SK, Agarwal P, Saxena R, Agrawal SS. Current concepts in the pathophysiology of glaucoma. Indian J Ophthalmol. 2009 Jul–Aug;57(4):257-66. doi: 10.4103/0301-4738.53049, PMID 19574692.

Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005 Apr 1;62(7):691-9. doi: 10.1093/ajhp/62.7.691, PMID 15790795.

Dimitrioua CD, DC. Pathophysiology of glaucoma. Future Medicine Ltd.; 2013.

Kaushik S, Pandav SS, Ram J. Neuroprotection in glaucoma. J Postgrad Med. 2003 Jan–Mar;49(1):90-5. doi: 10.4103/0022-3859.917, PMID 12865582.

Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995 Apr;36(5):774-86. PMID 7706025.

Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E. Nitric oxide (NO): an emerging target for the treatment of glaucoma. Invest Ophthalmol Vis Sci. 2014 Aug 14;55(8):5005-15. doi: 10.1167/iovs.14-14515, PMID 25125670.

Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007 Jan;87(1):315-424. doi: 10.1152/physrev.00029.2006, PMID 17237348.

Wong VH, Bui BV, Vingrys AJ. Clinical and experimental links between diabetes and glaucoma. Clin Exp Optom. 2011 Jan;94(1):4-23. doi: 10.1111/j.1444-0938.2010.00546.x, PMID 21091536.

Kuehn MH, Fingert JH, Kwon YH. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. Ophthalmol Clin North Am. 2005 Sep;18(3):383-95, vi. doi: 10.1016/j.ohc.2005.04.002, PMID 16054996.

Pendergast SD. Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid. Curr Opin Ophthalmol. 1998 Jun;9(3):71-5. doi: 10.1097/00055735-199806000-00013, PMID 10182105.

Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003 Jan;22(1):1-29. doi: 10.1016/s1350-9462(02)00043-5, PMID 12597922.

Josh Z, Yuen OD. Reconsider your approach to diabetic retionopathy. Rev Optom. 2015 Jun:28-9.

Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA. 1999 Sep 14;96(19):10836-41. doi: 10.1073/pnas.96.19.10836, PMID 10485912.

Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005 Jul;15(7):16R-28R. doi: 10.1093/glycob/cwi053, PMID 15764591.

Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003 Sep;110(9):1677-82. doi: 10.1016/S0161-6420(03)00475-5, PMID 13129861.

Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011 Sep;30(5):343-58. doi: 10.1016/j.preteyeres.2011.05.002, PMID 21635964.

Wilkinson Berka JL, Agrotis A, Deliyanti D. The retinal renin-angiotensin system: roles of angiotensin II and aldosterone. Peptides. 2012 Jul;36(1):142-50. doi: 10.1016/j.peptides.2012.04.008, PMID 22537944.

Gao S, Qin T, Liu Z, Caceres MA, Ronchi CF, Chen CY, Yeum KJ, Taylor A, Blumberg JB, Liu Y, Shang F. Lutein and zeaxanthin supplementation reduces H2O2-induced oxidative damage in human lens epithelial cells. Mol Vis. 2011;17:3180-90. PMID 22194644.

Bruno G, Costantino L, Curinga C, Maccari R, Monforte F, Nicoló F, Ottanà R, Vigorita MG. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg Med Chem. 2002 Apr;10(4):1077-84. doi: 10.1016/s0968-0896(01)00366-2, PMID 11836118.

Pegklidou K, Nicolaou I, Demopoulos VJ. Nutritional overview on the management of type 2 diabetes and the prevention of its complications. Curr Diabetes Rev. 2010 Nov;6(6):400-9. doi: 10.2174/157339910793499083, PMID 20879970.

Chatzopoulou M, Alexiou P, Kotsampasakou E, Demopoulos VJ. Novel aldose reductase inhibitors: a patent survey (2006--present). Expert Opin Ther Pat. 2012 Nov;22(11):1303-23. doi: 10.1517/13543776.2012.726615, PMID 22998509.

Leuenberger PM. Diabetic cataract and flavonoids (first results) (author’s transl) [Diabetic cataracts, and flavonoids (first results) (author’s transl)]. Klin Monbl Augenheilkd. 1978 Apr;172(4):460-2. PMID 418268.

Huang R, Shi F, Lei T, Song Y, Hughes CL, Liu G. Effect of the isoflavone genistein against galactose-induced cataracts in rats. Exp Biol Med (Maywood). 2007 Jan;232(1):118-25. PMID 17202592.

Moghaddam MS, Kumar PA, Reddy GB, Ghole VS. Effect of Diabecon on sugar-induced lens opacity in organ culture: mechanism of action. J Ethnopharmacol. 2005 Feb 28;97(2):397-403. doi: 10.1016/j.jep.2004.11.032, PMID 15707781.

Matsumoto T, Ono Y, Kuromiya A, Toyosawa K, Ueda Y, Bril V. Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats. J Pharmacol Sci. 2008 Jul;107(3):340-8. doi: 10.1254/jphs.08071fp, PMID 18612195.

Mucke HAM, Mucke E, Mucke PM. Aldose reductase inhibitors for diabetic cataracts: A study of disclosure patterns in patents, and peer review papers. Ophthalmol res. Int J. 2014 Jan;2(3):137-49.

Jaiswal S. Ss T, Mishra S. Neuroprotective effect of epalrestat on memory impairment in streptozotocin-induced type-2 diabetic rats using different behavioral models. Asian J Pharm Clin Res. 2018 Jan 1:411-5.

Suzen S, Buyukbingol E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr Med Chem. 2003 Aug;10(15):1329-52. doi: 10.2174/0929867033457377, PMID 12871133.

Kojima M, Sun L, Hata I, Sakamoto Y, Sasaki H, Sasaki K. Efficacy of alpha-lipoic acid against diabetic cataract in rat. Jpn J Ophthalmol. 2007 Jan–Feb;51(1):10-3. doi: 10.1007/s10384-006-0384-3, PMID 17295134.

Durukan AH, Evereklioglu C, Hurmeric V, Kerimoglu H, Erdurman C, Bayraktar MZ, Mumcuoglu T. Ingestion of IH636 grape seed proanthocyanidin extract to prevent selenite-induced oxidative stress in experimental cataracts. J Cataract Refract Surg. 2006 Jun;32(6):1041-5. doi: 10.1016/j.jcrs.2006.02.041, PMID 16814068.

Biswas S, Harris F, Singh J, Phoenix D. Role of calpains in diabetes mellitus-induced cataractogenesis: a mini review. Mol Cell Biochem. 2004 Jun;261(1-2):151-9. doi: 10.1023/b:mcbi.0000028750.78760.6f, PMID 15362498.

McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem. 1969 Nov 25;244(22):6049-55. doi: 10.1016/S0021-9258(18)63504-5, PMID 5389100.

Yan Q, Liu JP, Li DW. Apoptosis in lens development and pathology. Differentiation. 2006 Jun;74(5):195-211. doi: 10.1111/j.1432-0436.2006.00068.x, PMID 16759286.

Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004 Apr 12;23(16):2861-74. doi: 10.1038/sj.onc.1207523, PMID 15077149.

Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review) [a review]. Free Radical Res Commun. 1992;17(4):221-37. doi: 10.3109/10715769209079515, PMID 1473734.

Doganay S, Borazan M, Iraz M, Cigremis Y. The effect of resveratrol in experimental cataract model formed by sodium selenite. Curr Eye Res. 2006 Feb;31(2):147-53. doi: 10.1080/02713680500514685, PMID 16500765.

Papucci L, Schiavone N, Witort E, Donnini M, Lapucci A, Tempestini A, Formigli L, Zecchi-Orlandini S, Orlandini G, Carella G, Brancato R, Capaccioli S. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem. 2003 Jul 25;278(30):28220-8. doi: 10.1074/jbc.M302297200, PMID 12736273.

McCarthy S, Somayajulu M, Sikorska M, Borowy-Borowski H, Pandey S. Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10. Toxicol Appl Pharmacol. 2004 Nov 15;201(1):21-31. doi: 10.1016/j.taap.2004.04.019, PMID 15519605.

Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545, PMID 21030723.

Monnier VM, Cerami A. Non-enzymatic glycosylation and browning of proteins in diabetes. Clin Endocrinol Metab. 1982 Jul;11(2):431-52. doi: 10.1016/s0300-595x(82)80023-6, PMID 6754164.

Clifford MN. Chlorogenic acids and other cinnamates- nature, occurrence, dietary burden, absorption and metabolism. J Sci Food Agric. 2000;80(7):1033-43. doi: 10.1002/(SICI)1097-0010(20000515)80:7<1033::AID-JSFA595>3.0.CO;2-T.

Morimitsu Y, Yoshida K, Esaki S, Hirota A. Protein glycation inhibitors from thyme (Thymus vulgaris). Biosci Biotechnol Biochem. 1995 Nov;59(11):2018-21. doi: 10.1271/bbb.59.2018, PMID 8541639.

Javadi MA, Zarei-Ghanavati S. Cataracts in diabetic patients: a review article. J Ophthalmic Vis Res. 2008 Jan;3(1):52-65. PMID 23479523.

Schmidl D, Schmetterer L, Garhofer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015 Mar;31(2):63-77. doi: 10.1089/jop.2014.0067, PMID 25587905.

Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res. 2011 Sep;93(3):271-83. doi: 10.1016/j.exer.2011.04.002, PMID 21524649.

Toris CB, Koepsell SA, Yablonski ME, Camras CB. Aqueous humor dynamics in ocular hypertensive patients. J Glaucoma. 2002 Jun;11(3):253-8. doi: 10.1097/00061198-200206000-00015, PMID 12140404.

Kalapesi FB, Coroneo MT, Hill MA. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br J Ophthalmol. 2005 Jun;89(6):758-63. doi: 10.1136/bjo.2004.053025, PMID 15923515.

Grieshaber MC, Flammer J. Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?--an exemplary analysis on the basis of two beta-blockers. Prog Retin Eye Res. 2010 Jan;29(1):79-93. doi: 10.1016/j.preteyeres.2009.08.002, PMID 19733652.

Pfeiffer N, Lamparter J, Gericke A, Grus FH, Hoffmann EM, Wahl J. Neuroprotection of medical IOP-lowering therapy. Cell Tissue Res. 2013 Aug;353(2):245-51. doi: 10.1007/s00441-013-1671-1, PMID 23836043.

Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014 Jan;5(1):30-43. doi: 10.1177/2040622313511286, PMID 24381726.

Kaur IP, Smitha R, Aggarwal D, Kapil M. Acetazolamide: future perspective in topical glaucoma therapeutics. Int J Pharm. 2002 Nov 6;248(1-2):1-14. doi: 10.1016/s0378-5173(02)00438-6, PMID 12429455.

Alagöz N, Tellioglu A, Bektasoglu DL, Yasar T, Basgil Pasaoglu I, Altan AC, Solmaz B, Basarır B. Do we conform with European glaucoma society guidelines in the medical treatment of primary open-angle glaucoma/ocular hypertension? Data from a real-life practice. J Ocul Pharmacol Ther. 2020 Dec;36(10):747-53. doi: 10.1089/jop.2020.0032, PMID 33326338.

Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002 Aug;47;Suppl 1:S53-64. doi: 10.1016/s0039-6257(02)00306-5, PMID 12204701.

Kumar B, Gupta SK, Saxena R, Srivastava S. Current trends in the pharmacotherapy of diabetic retinopathy. J Postgrad Med. 2012 Apr–Jun;58(2):132-9. doi: 10.4103/0022-3859.97176, PMID 22718058.

Al Rashaed S, Arevalo JF. Combined therapy for diabetic macular edema. Middle East Afr J Ophthalmol. 2013 Oct–Dec;20(4):315-20. doi: 10.4103/0974-9233.120014, PMID 24339681.

Cho WB, Moon JW, Kim HC. Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. Br J Ophthalmol. 2010 Jul;94(7):858-63. doi: 10.1136/bjo.2009.168997, PMID 20606024.

Daull P, Paterson CA, Kuppermann BD, Garrigue JS. A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema. J Ocul Pharmacol Ther. 2013 Mar;29(2):258-69. doi: 10.1089/jop.2012.0044, PMID 23331052.

Fung WE. The national, prospective, randomized vitrectomy study for chronic aphakic cystoid macular edema. Progress report and comparison between the control and nonrandomized groups. Progress report. Surv Ophthalmol. 1984 May;28;Suppl:569-75. doi: 10.1016/0039-6257(84)90240-6, PMID 6463852.

Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, Taylor HR, Welborn TA, Zimmet PZ, AusDiab Study Group. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003 Jun;26(6):1731-7. doi: 10.2337/diacare.26.6.1731, PMID 12766102.

Sfikakis PP, Markomichelakis N, Theodossiadis GP, Grigoropoulos V, Katsilambros N, Theodossiadis PG. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care. 2005 Feb;28(2):445-7. doi: 10.2337/diacare.28.2.445, PMID 15677814.

Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004 May;3(5):391-400. doi: 10.1038/nrd1381, PMID 15136787.

Spielberg L, Leys A. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol. 2010 Jul;248(7):943-56. doi: 10.1007/s00417-009-1256-6, PMID 20204659.

Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M. Comparison of the effectiveness and prognostic factors of intravitreal ranibizumab between typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 24 months of follow-Up. Ophthalmologica. 2015 Jun;234(1):33-9. doi: 10.1159/000431000, PMID 26112059.

Siegel AB, Goyal A, Salomao M, Wang S, Lee V, Hsu C, Rodriguez R, Hershman DL, Brown RS Jr, Neugut AI, Emond J, Kato T, Samstein B, Faleck D, Karagozian R. Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. Oncology. 2015;88(1):57-68. doi: 10.1159/000367971, PMID 25300295.

Takahashi K, Saishin Y, Saishin Y, King AG, Levin R, Campochiaro PA. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol. 2009 Apr;127(4):494-9. doi: 10.1001/archophthalmol.2009.27, PMID 19365030.

Kuppermann BD, Thomas EL, de Smet MD, Grillone LR, Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 Oct;140(4):585-97. doi: 10.1016/j.ajo.2005.06.022, PMID 16226510.

Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, Holahan JR, Lee S, Wang Z, Badros A. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol. 2015 Mar 1;33(7):732-9. doi: 10.1200/JCO.2013.52.3522, PMID 25225420.

Halim EM, Mukhopadhyay AK. Effect of ocimum sanctum (Tulsi) and vitamin E on biochemical parameters and retinopathy in streptozotocin induced diabetic rats. Indian J Clin Biochem. 2006 Sep;21(2):181-8. doi: 10.1007/BF02912939, PMID 23105641.

Agrawal SS, Naqvi S, Gupta SK, Srivastava S. Prevention and management of diabetic retinopathy in STZ diabetic rats by Tinospora cordifolia and its molecular mechanisms. Food Chem Toxicol. 2012 Sep;50(9):3126-32. doi: 10.1016/j.fct.2012.05.057, PMID 22687550.

Wang CZ, Basila D, Aung HH, Mehendale SR, Chang WT, McEntee E, Guan X, Yuan CS. Effects of ganoderma lucidum extract on chemotherapy-induced nausea and vomiting in a rat model. Am J Chin Med. 2005;33(5):807-15. doi: 10.1142/S0192415X05003429, PMID 16265993.

Gupta SK, Kumar B, Nag TC, Agrawal SS, Agrawal R, Agrawal P, Saxena R, Srivastava S. Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J Ocul Pharmacol Ther. 2011 Apr;27(2):123-30. doi: 10.1089/jop.2010.0123, PMID 21314438.

Steigerwalt R, Belcaro G, Cesarone MR, Di Renzo A, Grossi MG, Ricci A, Dugall M, Cacchio M, Schönlau F. Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy. J Ocul Pharmacol Ther. 2009 Dec;25(6):537-40. doi: 10.1089/jop.2009.0023, PMID 19916788.

Kumar VL, Padhy BM. Protective effect of aqueous suspension of dried latex of Calotropis procera against oxidative stress and renal damage in diabetic rats. Biocell. 2011 Dec;35(3):63-9. doi: 10.32604/biocell.2011.35.063, PMID 22423482.

Chen Y, Li XX, Xing NZ, Cao XG. Quercetin inhibits choroidal and retinal angiogenesis in vitro. Graefes Arch Clin Exp Ophthalmol. 2008 Mar;246(3):373-8. doi: 10.1007/s00417-007-0728-9, PMID 18087712.

Nathiya S, Durga M, Devasena T. Quercetin, encapsulated quercetin, and its application- A review. Int J Pharm Pharm Sci. 2014 Oct;6(10):20-6.

Kowluru RA, Atasi L, Ho YS. Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1594-9. doi: 10.1167/iovs.05-1276, PMID 16565397.

Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM, UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004 Nov;122(11):1631-40. doi: 10.1001/archopht.122.11.1631, PMID 15534123.

Kim JH, Lee BJ, Kim JH, Yu YS, Kim KW. Anti-angiogenic effect of caffeic acid on retinal neovascularization. Vasc Pharmacol. 2009 Oct;51(4):262-7. doi: 10.1016/j.vph.2009.06.010, PMID 19589397.

Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes. 2004 Dec;53(12):3233-8. doi: 10.2337/diabetes.53.12.3233, PMID 15561955.

Petersen M, Simmonds MS. Rosmarinic acid. Phytochemistry. 2003 Jan;62(2):121-5. doi: 10.1016/s0031-9422(02)00513-7, PMID 12482446.

Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003 Mar;9(3):294-9. doi: 10.1038/nm834, PMID 12592403.

Moustafa SA. Zinc might protect oxidative changes in the retina and pancreas at the early stage of diabetic rats. Toxicol Appl Pharmacol. 2004 Dec 1;201(2):149-55. doi: 10.1016/j.taap.2004.05.014, PMID 15541754.

Lal VK, Verma A. Development and evaluation of ophthalmic drop and in-situ gel from roots of boerhaavia diffusa. BJPR. 2016 Mar 21;11(1):1-20. doi: 10.9734/BJPR/2016/24395.

Velpandian T, Nirmal J, Gupta P, Vijayakumar AR, Ghose S. Evaluation of calcium dobesilate for its anti-cataract potential in experimental animal models. Methods Find Exp Clin Pharmacol. 2010 Apr;32(3):171-9. doi: 10.1358/mf.2010.32.3.1423888, PMID 20448859.

Jonnalagadd VG, Selkar N. Antidiabetic herbal products marketed in India: an update. J Med Plants Stud. 2013;1(6):24-6.

Tanito M, Hara K, Takai Y, Matsuoka Y, Nishimura N, Jansook P, Loftsson T, Stefánsson E, Ohira A. Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011 Oct 10;52(11):7944-8. doi: 10.1167/iovs.11-8178, PMID 21896859.

Mazzolani F, Togni S, Giacomelli L, Eggenhoffner R, Franceschi F. Oral administration of a curcumin-phospholipid formulation (Meriva®) for treatment of chronic diabetic macular edema: a pilot study. Eur Rev Med Pharmacol Sci. 2018 Jun;22(11):3617-25. doi: 10.26355/eurrev_201806_15189, PMID 29917217.

Chae JB, Joe SG, Yang SJ, Lee JY, Sung KR, Kim JY, Kim JG, Yoon YH. Effect of combined cataract surgery and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy. Retina. 2014 Jan;34(1):149-56. doi: 10.1097/IAE.0b013e3182979b9e, PMID 23807186.

Ragasa CY, Lorena GS, M, andia EH, Raga DD, Shen CC. Chemical constituents of Abrus precatorius. Am J Essent Oils Nat Prod. 2013;1(2):7-10.

Radha MH, Laxmipriya NP. Evaluation of biological properties and clinical effectiveness of Aloe vera: A systematic review. J Tradit Complement Med. 2015;5(1):21-6. doi: 10.1016/j.jtcme.2014.10.006, PMID 26151005.

Narayana DB, Durg S, Manohar PR, Mahapatra A, Aramya AR. Chyawanprash: A review of therapeutic benefits as in authoritative texts and documented clinical literature. J Ethnopharmacol. 2017 Feb 2;197:52-60. doi: 10.1016/j.jep.2016.07.078, PMID 27496580.

Boti JB, Koukoua G, N’Guessan TY, Casanova J. Chemical variability ofConyza sumatrensis andMicroglossa pyrifolia from Côte d’Ivoire. Flavour Fragr J. 2007 Jan;22(1):27-31. doi: 10.1002/ffj.1743.

Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic preparations of acetazolamide. Int J Pharm. 2000 Apr 20;199(2):119-27. doi: 10.1016/s0378-5173(00)00359-8, PMID 10802405.

Crim N, Velez Montoya R, Morales Canton V. Surgical versus medical treatment for diabetic macular edema: a review. Med Hypothesis Discov Innov Ophthalmol. 2017 Winter;6(4):136-42. PMID 29560368.

Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol. 2008 Dec;2(4):689-92. doi: 10.2147/opth.s3965, PMID 19668417.

Weisz JM, Bressler NM, Bressler SB, Schachat AP. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology. 1999 Sep;106(9):1656-9. doi: 10.1016/S0161-6420(99)90366-4, PMID 10485530.

Kataria P, Katara R, Sahoo PK, Sachdeva S. Dorzolamide in situ gel forming system: characterization and evaluation for glaucoma treatment. Madridge J Pharm Res. 2017;1(1):13-21. doi: 10.18689/mjpr-1000103.

Mortazavi SA, Jafariazar Z, Ghadjahani Y, Mahmoodi H, Mehtarpour F. Formulation and in vitro characterization of sustained release matrix type ocular timolol maleate mini-tablet. Iran J Pharm Res. 2014;13(1):19-27. PMID 24734053.

Emad Eldeeb A, Salah S, Ghorab M. Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in vitro characterization, and in vivo pharmacodynamic study. Drug Deliv. 2019 Dec;26(1):509-21. doi: 10.1080/ 10717544.2019.1609622, PMID 31090464.

Dubey A, Prabhu P. Formulation and evaluation of stimuli-sensitive hydrogels of timolol maleate and brimonidine tartrate for the treatment of glaucoma. Int J Pharm Investig. 2014 Jul;4(3):112-8. doi: 10.4103/2230-973X.138340, PMID 25126524.

Alvarez Rivera F, Concheiro A, Alvarez Lorenzo C. Epalrestat-loaded silicone hydrogels as contact lenses to address diabetic-eye complications. Eur J Pharm Biopharm. 2018 Jan;122:126-36. doi: 10.1016/j.ejpb.2017.10.016, PMID 29079419.

Ali Z, Sharma PK, Warsi MH. Fabrication and evaluation of ketorolac loaded cubosome for ocular drug delivery. J App Pharm Sci. 2016 Sep;6(09):204-8. doi: 10.7324/JAPS.2016.60930.

Huang J, Peng T, Li Y, Zhan Z, Zeng Y, Huang Y, Pan X, Wu CY, Wu C. Ocular cubosome drug delivery system for timolol maleate: preparation, characterization, cytotoxicity, ex vivo, and in vivo evaluation. AAPS PharmSciTech. 2017 Nov;18(8):2919-26. doi: 10.1208/s12249-017-0763-8, PMID 28429294.

Meza Rios A, Navarro Partida J, Armendariz Borunda J, Santos A. Therapies based on nanoparticles for eye drug delivery. Ophthalmol Ther. 2020 Sep;9(3):1-14. doi: 10.1007/s40123-020-00257-7, PMID 32383107.

Natarajan JV, Ang M, Darwitan A, Chattopadhyay S, Wong TT, Venkatraman SS. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int J Nanomed. 2012;7:123-31. doi: 10.2147/IJN.S25468, PMID 22275828.

Li H, Liu Y, Zhang Y, Fang D, Xu B, Zhang L, Chen T, Ren K, Nie Y, Yao S, Song X. Liposomes as a novel ocular delivery system for brinzolamide: In vitro and in vivo studies. AAPS PharmSciTech. 2016 Jun;17(3):710-7. doi: 10.1208/s12249-015-0382-1, PMID 26335415.

Katiyar S, Pandit J, Mondal RS, Mishra AK, Chuttani K, Aqil M, Ali A, Sultana Y. In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma. Carbohydr Polym. 2014 Feb 15;102:117-24. doi: 10.1016/j.carbpol.2013.10.079, PMID 24507263.

Warsi MH, Anwar M, Garg V, Jain GK, Talegaonkar S, Ahmad FJ, Khar RK. Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits. Colloids Surf B Biointerfaces. 2014 Oct 1;122:423-31. doi: 10.1016/j.colsurfb.2014.07.004, PMID 25159319.

Jain K, Kumar RS, Sood S, Dhyanandhan G. Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery and their anti-glaucoma efficacy. Curr Drug Deliv. 2013 Oct;10(5):493-9. doi: 10.2174/1567201811310050001, PMID 23410069.

Ibrahim MM, Abd-Elgawad AE, Soliman OA, Jablonski MM. Novel topical ophthalmic formulations for management of glaucoma. Pharm Res. 2013 Nov;30(11):2818-31. doi: 10.1007/s11095-013-1109-1, PMID 23771565.

Wang F, Chen L, Jiang S, He J, Zhang X, Peng J, Xu Q, Li R. Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design. J Liposome Res. 2014 Sep;24(3):171-81. doi: 10.3109/08982104.2014.891231, PMID 24611687.

El-Salamouni NS, Farid RM, El-Kamel AH, El-Gamal SS. Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Int J Pharm. 2015 Dec 30;496(2):976-83. doi: 10.1016/j.ijpharm.2015.10.043, PMID 26498372.

Leonardi A, Bucolo C, Drago F, Salomone S, Pignatello R. Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit. Int J Pharm. 2015 Jan 15;478(1):180-6. doi: 10.1016/j.ijpharm.2014.11.032, PMID 25448580.

Wang F, Chen L, Zhang D, Jiang S, Shi K, Huang Y, Li R, Xu Q. Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: in vitro and in vivo study. J Drug Target. 2014 Nov;22(9):849-58. doi: 10.3109/1061186X.2014.939983, PMID 25045926.

Fahmy HM, Saad EAES, Sabra NM, El-Gohary AA, Mohamed FF, Gaber MH. Treatment merits of latanoprost/thymoquinone- Encapsulated liposome for glaucomatus rabbits. Int J Pharm. 2018 Sep 5;548(1):597-608. doi: 10.1016/j.ijpharm.2018.07.012, PMID 29997042.

Mokhtar Ibrahim M, Tawfique SA, Mahdy MM. Liposomal diltiazem HCl as ocular drug delivery system for glaucoma. Drug Dev Ind Pharm. 2014 Jun;40(6):765-73. doi: 10.3109/03639045.2013.783589, PMID 23570512.

Yu S, Wang QM, Wang X, Liu D, Zhang W, Ye T, Yang X, Pan W. Liposome incorporated ion sensitive in situ gels for opthalmic delivery of timolol maleate. Int J Pharm. 2015 Mar 1;480(1-2):128-36. doi: 10.1016/j.ijpharm.2015.01.032, PMID 25615987.

Gagandeep, Garg T, Malik B, Rath G, Goyal AK. Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci. 2014 Mar 12;53:10-6. doi: 10.1016/j.ejps.2013.11.016, PMID 24333373.

Aburahma MH, Mahmoud AA. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation. AAPS PharmSciTech. 2011 Dec;12(4):1335-47. doi: 10.1208/s12249-011-9701-3, PMID 21979886.

Fulgencio Gde O, Viana FA, Ribeiro RR, Yoshida MI, Faraco AG, Cunha Junior Ada S. New mucoadhesive chitosan film for ophthalmic drug delivery of timolol maleate: in vivo evaluation. J Ocul Pharmacol Ther. 2012 Aug;28(4):350-8. doi: 10.1089/jop.2011.0174, PMID 22320419.

Kashiwagi K, Ito K, Haniuda H, Ohtsubo S, Takeoka S. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma. Invest Ophthalmol Vis Sci. 2013 Aug 19;54(8):5629-37. doi: 10.1167/iovs.12-9513, PMID 23868986.

Ribeiro A, Veiga F, Santos D, Torres Labandeira JJ, Concheiro A, Alvarez-Lorenzo C. Bioinspired imprinted PHEMA-hydrogels for ocular delivery of carbonic anhydrase inhibitor drugs. Biomacromolecules. 2011 Mar 14;12(3):701-9. doi: 10.1021/bm101562v, PMID 21314109.

Hao X, Han Z, Zhu C. Topical composition for treating diabetic cataracts: a patent evaluation (WO2015026380A1). Expert Opin Ther Pat. 2016 Jun;26(6):731-5. doi: 10.1517/13543776.2016.1163339, PMID 26967920.

Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M, Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008 Oct;146(4):554-60. doi: 10.1016/j.ajo.2008.04.036, PMID 18599019. ajo.2008.04.036.

Yuksel B, Karti O, Kusbeci T. Topical nepafenac for prevention of post-cataract surgery macular edema in diabetic patients: patient selection and perspectives. Clin Ophthalmol. 2017 Dec 11;11:2183-90. doi: 10.2147/OPTH.S132810, PMID 29269999.

Julius A, Hopper W. A non-invasive, multi-target approach to treat diabetic retinopathy. Biomed Pharmacother. 2019 Jan;109:708-15. doi: 10.1016/j.biopha.2018.10.185, PMID 30551523.

Rossetti L, Iester M, Tranchina L, Ottobelli L, Coco G, Calcatelli E, Ancona C, Cirafici P, Manni G. Can treatment with citicoline eyedrops reduce progression in glaucoma? The results of a randomized placebo-controlled clinical trial. J Glaucoma. 2020 Jul;29(7):513-20. doi: 10.1097/IJG.0000000000001565, PMID 32541370.



How to Cite




Review Article(s)

Most read articles by the same author(s)